Neuberger Berman Group LLC Grows Stake in Glaukos Co. (NYSE:GKOS)

Neuberger Berman Group LLC grew its holdings in Glaukos Co. (NYSE:GKOSFree Report) by 29.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 59,218 shares of the medical instruments supplier’s stock after acquiring an additional 13,469 shares during the quarter. Neuberger Berman Group LLC owned about 0.12% of Glaukos worth $4,707,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in GKOS. Nomura Holdings Inc. grew its stake in Glaukos by 3.2% during the 4th quarter. Nomura Holdings Inc. now owns 232,034 shares of the medical instruments supplier’s stock worth $18,444,000 after buying an additional 7,146 shares during the last quarter. Rhenman & Partners Asset Management AB grew its stake in Glaukos by 64.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 120,000 shares of the medical instruments supplier’s stock worth $9,539,000 after buying an additional 47,000 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Glaukos during the 4th quarter worth approximately $1,697,000. Allianz Asset Management GmbH grew its stake in Glaukos by 2.0% during the 4th quarter. Allianz Asset Management GmbH now owns 56,043 shares of the medical instruments supplier’s stock worth $4,455,000 after buying an additional 1,100 shares during the last quarter. Finally, TD Asset Management Inc purchased a new position in Glaukos during the 4th quarter worth approximately $3,056,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Alex R. Thurman sold 434 shares of the business’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $95.33, for a total value of $41,373.22. Following the transaction, the chief financial officer now owns 54,166 shares in the company, valued at $5,163,644.78. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Alex R. Thurman sold 434 shares of the business’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $95.33, for a total value of $41,373.22. Following the transaction, the chief financial officer now owns 54,166 shares in the company, valued at $5,163,644.78. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 2,500 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $113.50, for a total value of $283,750.00. Following the completion of the transaction, the chief operating officer now owns 101,845 shares in the company, valued at approximately $11,559,407.50. The disclosure for this sale can be found here. Insiders have sold a total of 81,475 shares of company stock worth $8,387,713 over the last quarter. 6.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. BTIG Research raised their price target on Glaukos from $107.00 to $112.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. Citigroup raised their price target on Glaukos from $120.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Wells Fargo & Company raised their price target on Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, June 3rd. Finally, JPMorgan Chase & Co. raised their price target on Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $112.27.

Check Out Our Latest Stock Report on GKOS

Glaukos Price Performance

Shares of NYSE GKOS traded down $2.72 during trading on Monday, reaching $111.19. The company had a trading volume of 168,731 shares, compared to its average volume of 594,013. The stock has a market capitalization of $5.60 billion, a PE ratio of -38.88 and a beta of 1.09. The company has a current ratio of 5.38, a quick ratio of 4.68 and a debt-to-equity ratio of 0.78. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $115.78. The stock has a 50-day moving average price of $104.09 and a two-hundred day moving average price of $90.96.

Glaukos (NYSE:GKOSGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). The company had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The company’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.59) EPS. As a group, sell-side analysts predict that Glaukos Co. will post -2.26 earnings per share for the current year.

About Glaukos

(Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Further Reading

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.